Dear Editor,
We read with great interest a case report on the use of etanercept in the management of refractory severe erythema nodosum leprosum (ENL) [1] . We appreciate that the authors managed the case successfully with this newer biologic. Managing refractory ENL reactions is an important and difficult task because of the patient's psychological stress, adverse effects, and poor responses to antireaction drugs. We understood this and have tried to clarify certain doubts regarding the management and mechanisms of action. In the case report it was mentioned that over 6 months, multiple extended courses of higher doses of prednisolone, clofazimine, thalidomide, minocycline, clarithromycin, ofloxacin, pentoxifylline, and azathioprine were used and the patient had few symptom-free periods and experienced many ENLrelated episodes with increased severity. We were surprised regarding the use of multiple drugs within a short period of 6 months. The use of the antibiotics minocycline (bacteriostatic), ofloxacin, and clarithromycin (bactericidal) daily for 6 months along with multidrug therapy is not understandable and is questionable as to whether they were used as additional antileprotic drugs or for necrotic ulcers to prevent sepsis. These drugs are used as an alternative or substitute in any resistance or contraindicated cases only as per World Health Organization protocol [2, 3] . In the article it was mentioned that after receiving etanercept for 12 weeks, the patient improved significantly, allowing for a slow taper and eventual discontinuation of prednisolone. This shows that the patient response may be due to a combinational effect of etanercept with prednisolone. The dosage of prednisolone at the start of taking etanercept is important for knowing patient clinical responses. As per World Health Organization protocol clofazimine may be used for up to 12 months in the management of severe ENL and the current usage in this particular case is not mentioned. After a month of tapering/stoppage of steroids the patient did not have any recurrence of ENL. The same reaction-free interval has also been achieved in the past. Therefore, we feel that there is a need for a longer followup period before making a conclusion on the response by etanercept alone. The patient had already completed seven pulses of multidrug therapy with additional bactericidal drugs for 6 months when the first dose of etanercept was given. By this time, the morphological index might be 0 with a rare reduction in bacterial index that might have contributed to the reduced risk of recurrence of ENL and its severity. The irrational use of additional drugs may trigger very severe necrotic lesions. Minocycline has the property of causing skin-related adverse effects [4] . The current status of this patient is mandated as the first case report on etanercept showing a single recurrence (treated with thalidomide for 3 months) with a 1-year reaction-free period of a patient who was treated for 2 years and followed-up for 2.5 years in a case of refractory ENL of 6-years duration [5] . From the two available case reports on etanercept we emphasize that etanercept can be an add-on drug with steroids/clofazimine/ thalidomide according to the situation. E-mail address: drpugal23@gmail.com (P. Thangaraju).
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